T. Rowe Price Investment Management Increases Stake in Dyne Therapeutics to 18.7%

On May 15, 2026, T. Rowe Price Investment Management, Inc. filed a Schedule 13G/A (Amendment No. 2) regarding its holdings in Dyne Therapeutics Inc (DYN). The filing discloses that as of March 31, 2026, the investment adviser beneficially owns 30,785,801 shares of common stock, representing an 18.7% ownership stake in the company. This marks a significant increase from previous reporting where holdings were not established at this level. Of the total shares held, T. Rowe Price Investment Management reports sole voting power over 30,419,012 shares and sole dispositive power over all 30,785,801 shares. The filing was made under Rule 13d-1(b), indicating the securities were acquired in the ordinary course of business without the intent to influence or change the control of the issuer. The total value of the position is estimated at approximately $532.3 million based on market data at the time of the event. T. Rowe Price Investment Management is based in Baltimore, Maryland, and serves as the reporting person for this institutional investment position.